B cell lymphoma 6 protein (BCL6) as a target for treating diabetes mellitus and non-alcoholic fatty liver disease
Disclosed are methods and compositions for treating diabetes mellitus and non-alcoholic fatty liver disease by administering a therapeutic agent that inhibits the biological activity of B cell lymphoma 6 protein (BCL6).
1. A method for treating non-alcoholic fatty liver disease in a subject in need thereof, the method comprising administering to the subject a therapeutic agent that inhibits the expression of B cell lymphoma protein 6 (BCL6).
2. The method of claim 1 , comprising inhibiting expression of BCL6 in adipocytes.
3. The method of claim 1 , comprising inhibiting expression of BCL6 in hepatocytes.
4. The method of claim 1 , wherein the method promotes insulin sensitivity.
5. The method of claim 1 , wherein the method prevents hepatic steatosis.
6. The method of claim 1 , wherein the method enhances glucose tolerance.
7. The method of claim 1 , wherein the method enhances glucose-stimulated insulin secretion.
8. The method of claim 1 , wherein the method prevents weight gain.